Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $2.83M | $6.24M | $2.04M |
| Revenue growth | — | — | — | — | — | — | — | — | 120.6% | -67.3% |
| Operating income | -$9.27M | -$35.7M | -$60.0M | -$83.0M | -$78.7M | -$74.7M | -$29.7M | -$48.2M | -$102M | -$178M |
| Operating margin | — | — | — | — | — | — | — | -1704.7% | -1633.7% | -8739.3% |
| Net income | -$9.43M | -$35.5M | -$57.5M | -$76.8M | -$74.9M | -$71.1M | -$28.5M | -$43.6M | -$85.0M | -$162M |
| Net margin | — | — | — | — | — | — | — | -1541.2% | -1362.8% | -7973.3% |
| EPS (diluted) | -$65.15 | -$19.12 | -$3.13 | -$2.07 | -$1.71 | -$1.29 | -$32.57 | -$8.45 | -$2.55 | -$4.20 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.53M | -$22.3M | -$41.9M | -$57.1M | -$64.0M | -$59.5M | -$29.1M | -$36.9M | -$78.2M | -$129M |
| Capital expenditures | $139K | $2.20M | $7.67M | $3.06M | $400K | $1.26M | $314K | — | — | — |
| Free cash flow | -$6.67M | -$24.5M | -$49.6M | -$60.2M | -$64.4M | -$60.8M | -$29.4M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.54M | $51.4M | $58.3M | $65.1M | $58.2M | $132M | $15.4M | $132M | $22.8M | $51.1M |
| Total assets | — | $54.5M | $157M | $162M | $162M | $190M | $83.1M | $179M | $374M | $531M |
| Total liabilities | — | $4.14M | $11.7M | $20.3M | $17.7M | $17.3M | $9.45M | $10.5M | $21.5M | $37.5M |
| Shareholders' equity | -$8.87M | -$42.1M | $146M | $141M | $144M | -$17.2M | -$44.4M | $169M | $352M | $493M |
| Retained earnings | — | -$45.2M | -$103M | -$179M | -$254M | -$326M | -$45.9M | -$89.4M | -$174M | -$337M |
| Shares (wtd avg diluted) | — | 2.35M | 33.3M | 39.3M | 43.9M | 54.9M | 874K | 5.15M | 33.3M | 38.6M |
Every figure is extracted from Dianthus Therapeutics, Inc. /DE/’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.